Abstract
PURPOSE: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer.
METHODS: This is a retrospective study of patients treated with ramucirumab plus paclitaxel.
RESULTS: Fifty-three patients were evaluated. Among these, 10 patients (26.5%) developed grade ≥3 neutropenia. Patients with grade ≥3 neutropenia reported a progression-free survival of 6.6 months (95% confidence interval 3.3-8.4) and overall survival of 11 months (95% confidence interval 5.9-13.1) vs. 4.4 months (95% confidence interval 3.9-5.2) and 8.7 months (95% confidence interval 7.8-10.1) respectively in patients' group with lower grade events.
CONCLUSION: Our analysis seems to suggest that the occurrence of neutropenia predicts response to treatment with ramucirumab and paclitaxel.
| Original language | English |
|---|---|
| Pages (from-to) | 632-636 |
| Journal | Anti-Cancer Drugs |
| Volume | 31 |
| Issue number | 6 |
| Early online date | 31 Jan 2020 |
| DOIs | |
| Publication status | Published - Jul 2020 |
Access to Document
- NeutroRam_161019_alb.PDF
this is the authors accepted manuscript of an article published in final form as Roviello, G, Conca, R, D'Angelo, A, Multari, AG, Paganini, G, Chiriacò, G, Petrioli, R, Corona, SP, Rosellini, P & Aieta, M 2020, 'Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer', Anti-Cancer Drugs. and available online via: https://dx.doi.org/10.1097/CAD.0000000000000905